Karyopharm Therapeutics affirms FY2026 sales guidance at $130M-$150M
Karyopharm Therapeutics (NASDAQ: KPTI) affirms FY2026 sales guidance of $130.000 million-$150.000 million versus a $133.736 million estimate, keeping the same range.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.